Struggling to Control Very High Triglyceride Levels? 

Quality Research Is Seeking Volunteers for Severe Hypertriglyceridemia (SHTG) Study

This clinical trial aims to evaluate a research medication that may help lower triglyceride levels, potentially offering a new avenue for treatment.

Why Participate in the SHTG Study?

If you’ve tried multiple treatments without success and are seeking new options to manage your condition, consider joining the Severe Hypertriglyceridemia (SHTG) Study in San Antonio, TX. Participants in the study can access an investigational medication designed to lower triglyceride levels. Your participation could significantly impact the future of severe hypertriglyceridemia treatment and contribute to medical research.

Understanding Severe Hypertriglyceridemia

Severe hypertriglyceridemia is defined as having triglyceride levels above 500 mg/dL, with dangerously high levels considered to be above 1,000 mg/dL. When triglyceride levels reach this threshold, the risk of pancreatitis—a potentially life-threatening inflammation of the pancreas—increases significantly, making it an emergency situation that requires immediate medical attention. Treatment for severely elevated triglycerides typically includes lifestyle changes such as a low-fat diet, regular exercise, and medications specifically designed to lower triglyceride levels. This study explores the efficacy of a new investigational medication in managing these extreme levels.

What is the study medication?

The investigational study medication, Pegozafermin, is an artificial form of a natural hormone called FGF21 that is made to last longer in the body than the natural form. This hormone is involved in the body’s processing and storage of energy through fats and sugars. People with SHTG often have low levels of FGF21, and researchers think having more may help their bodies process fats and sugars better and lead to lower TG levels. Pegozafermin is also designed to stay in the body longer than natural FGF21, giving it more time to help lower high triglycerides. Pegozafermin is an investigational medication, which means it has not been approved by any health or regulatory agency as an option for managing severe hypertriglyceridemia.

Will I receive the study medication?

Only some people in the study receive Pegozafermin. About 1 in 4 participants receive a placebo, which looks like Pegozafermin and is also given by injection but has no active ingredients. Neither you nor the study doctor or staff will know whether you are receiving Pegozafermin or a placebo.

Compensation for Time and Travel

As a thank you for your time and commitment, eligible participants may receive compensation of up to $2,225 for their time, travel, and expenses related to the study visits. This is an excellent opportunity to contribute to medical research while being compensated for your effort.

Do I Qualify?

If you are interested in learning more about the Severe Hypertriglyceridemia (SHTG) Study and want to see if you qualify, click here. Your participation could lead to new treatments and provide valuable insights into managing high triglyceride levels.

Advancing Health, One Study at a Time

The Quality Research clinical trials team is dedicated to advancing medical knowledge and improving patient care through rigorous and ethical research practices. Our team of experienced professionals is committed to providing high-quality medical care and ensuring the safety and well-being of all study participants. We work tirelessly to bring innovative treatments to those who need them most, always with a focus on compassion and excellence in clinical research.